Table 1.
Baseline clinical characteristics of patients with favorable and unfavorable outcomes following EVT for tandem internal carotid and middle cerebral artery occlusion.
| Characteristics | All n = 53 | Favorable Outcome (mRS 0–2) n = 20 (37.7%) |
Unfavorable Outcome (mRS 3–6) n = 33 (62.3%) |
p Value |
|---|---|---|---|---|
| Age, median, IQR | 75.9 (64.6–82.6) | 66.5 (60.5–78.5) | 79.0 (72.0–84.0) | 0.011 |
| Male gender (%) | 28 (52.8) | 12 (60.0) | 16 (48.5) | 0.567 |
| Premorbid mRS 2–4 (%) | 5 (9.3) | 1 (5.0) | 9 (27.3) | 0.295 |
| Admission NIHSS score IQR | 20 (16–23) | 18 (16–22) | 22 (16–23) | 0.317 |
| Discharge NIHSS score (n = 39) IQR | 19 (10–18) | 9 (4–16) | 15 (10–18) | <0.001 |
| TOAST Classification | ||||
| Cardioembolism and unknown (%) | 38 (71.6) | 11 (55.0) | 27 (81.8) | 0.058 |
| Large artery | 9 (17.0) | 4 (20) | 5 (15.2) | |
| Other causes (%) | 6 (11.3) | 5 (25.0) | 1 (30.0) | |
| Risk Factors | ||||
| TIA/stroke (%) | 11 (20.7) | 4 (20.0) | 6 (18.2) | 1.000 |
| Peripheral arterial occlusive disease (%) | 9 (16.9) | 2 (10.0) | 7 (21.2) | 0.456 |
| Atrial fibrillation (%) | 21 (39.6) | 8 (40.0) | 13 (39.4) | 1.000 |
| Diabetes (%) | 17 (13.2) | 3 (15.0) | 4 (12.1) | 1.000 |
| Arterial hypertension (%) | 32 (60.4) | 9 (45.0) | 23 (69.7) | 0.090 |
| Carotid stenosis ≥50% (%) | 12 (22.6) | 5 (25.0) | 7 (21.1) | 0.748 |
| Glucose (n = 51), mg/dL | 129 (115–146) | 122 (106–136) | 130 (117–161) | 0.050 |
| Cholesterol (n = 45), mg/dL | 158 (132–184) | 175 (147–208) | 143 (123–171) | 0.026 |
| LDL (n = 43), mg/dL | 93 (72–116) | 108 (92–131) | 82 (65–102) | 0.011 |
| Erythrocyte count (n = 47) | 4.5 (4.1–4.8) | 4.6 (4.4–4.8) | 4.2 (3.9–4.6) | 0.017 |
| Thrombocyte count (n = 47) | 229 (188–299) | 264 (198–341) | 214 (170–260) | 0.061 |
| Antithrombotic Treatment Before Stroke | ||||
| Aspirin (%) | 16 (30.2) | 6 (30.0) | 9 (27.3) | 1.000 |
| Anticoagulant (%) | 9 (16.9) | 4 (20.0) | 5 (15.1) | 0.715 |
Abbreviations: EVT—endovascular treatment; NIHSS—National Institutes of Health Stroke scale; mRS—modified Rankin scale; TOAST—Trial of Org 10172 in Acute Stroke Treatment. Values in parentheses refers to interquartile range (IQR).